314 related articles for article (PubMed ID: 26231668)
1. Expression array analysis of the hepatocyte growth factor invasive program.
Cecchi F; Lih CJ; Lee YH; Walsh W; Rabe DC; Williams PM; Bottaro DP
Clin Exp Metastasis; 2015 Oct; 32(7):659-76. PubMed ID: 26231668
[TBL] [Abstract][Full Text] [Related]
2. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
3. The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation.
Mungunsukh O; Lee YH; Bottaro DP; Day RM
Cell Signal; 2016 Aug; 28(8):1114-23. PubMed ID: 27224506
[TBL] [Abstract][Full Text] [Related]
4. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis.
Day RM; Cioce V; Breckenridge D; Castagnino P; Bottaro DP
Oncogene; 1999 Jun; 18(22):3399-406. PubMed ID: 10362361
[TBL] [Abstract][Full Text] [Related]
5. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
6. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
7. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.
Rubin JS; Day RM; Breckenridge D; Atabey N; Taylor WG; Stahl SJ; Wingfield PT; Kaufman JD; Schwall R; Bottaro DP
J Biol Chem; 2001 Aug; 276(35):32977-83. PubMed ID: 11435444
[TBL] [Abstract][Full Text] [Related]
9. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells.
Yin YL; Chen HL; Kuo HM; He SP
Acta Pharmacol Sin; 2008 Jun; 29(6):728-35. PubMed ID: 18501120
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
11. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
12. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
13. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.
Otsuka T; Jakubczak J; Vieira W; Bottaro DP; Breckenridge D; Larochelle WJ; Merlino G
Mol Cell Biol; 2000 Mar; 20(6):2055-65. PubMed ID: 10688652
[TBL] [Abstract][Full Text] [Related]
14. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
15. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions.
Atabey N; Gao Y; Yao ZJ; Breckenridge D; Soon L; Soriano JV; Burke TR; Bottaro DP
J Biol Chem; 2001 Apr; 276(17):14308-14. PubMed ID: 11278639
[TBL] [Abstract][Full Text] [Related]
16. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
17. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
19. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
20. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H
Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]